
JAVIER
LECETA MARTÍNEZ
Catedrático de universidad
Publications (98) JAVIER LECETA MARTÍNEZ publications
2023
-
Editorial: Community series in immunoregulation at mucosal surfaces volume II
Frontiers in Immunology
-
Editorial: Overcoming challenges in mucosal immunity: 2022
Frontiers in Immunology
2022
-
Editorial: Immunoregulation at mucosal surfaces
Frontiers in Immunology
-
Editorial: The innate immune system in rheumatoid arthritis
Frontiers in Immunology
2021
-
Mechanism of Immunoregulatory Properties of Vasoactive Intestinal Peptide in the K/BxN Mice Model of Autoimmune Arthritis
Frontiers in Immunology, Vol. 12
2018
-
Inhibitory role of growth hormone in the induction and progression phases of collagen-induced arthritis
Frontiers in Immunology, Vol. 9, Núm. MAY
2016
-
Healthy and Osteoarthritic Synovial Fibroblasts Produce a Disintegrin and Metalloproteinase with Thrombospondin Motifs 4, 5, 7, and 12: Induction by IL-1β and Fibronectin and Contribution to Cartilage Damage
American Journal of Pathology, Vol. 186, Núm. 9, pp. 2449-2461
2015
-
Th17 polarization of memory Th cells in early arthritis: The vasoactive intestinal peptide effect
Journal of Leukocyte Biology, Vol. 98, Núm. 2, pp. 257-269
-
The pathogenic Th profile of human activated memory Th cells in early rheumatoid arthritis can be modulated by VIP
Journal of Molecular Medicine, Vol. 93, Núm. 4, pp. 457-467
2014
-
Serum Levels of Vasoactive Intestinal Peptide as a Prognostic Marker in Early Arthritis
PLoS ONE, Vol. 9, Núm. 1
-
Vasoactive Intestinal Peptide Maintains the Nonpathogenic Profile of Human Th17-Polarized Cells
Journal of Molecular Neuroscience, Vol. 54, Núm. 3, pp. 512-525
2013
-
Vasoactive Intestinal Peptide Serum Levels As a Marker Of Prognosis In Rheumatoid Arthritis.
ARTHRITIS AND RHEUMATISM
2012
-
Effect of VIP on the balance between cytokines and master regulators of activated helper T cells
Immunology and Cell Biology, Vol. 90, Núm. 2, pp. 178-186
-
VIP in inflammatory bowel disease: State of the art
Endocrine, Metabolic and Immune Disorders - Drug Targets, Vol. 12, Núm. 4, pp. 316-322
2011
-
Differential expression pattern of pituitary adenylate cyclase-activating polypeptide (PACAP) alternative splicing variants and its receptors in the immune system of rainbow trout (Oncorhynchus mykiss)
Fish and Shellfish Immunology, Vol. 30, Núm. 2, pp. 734-738
2010
-
New insights into the role of VIP on the ratio of T-cell subsets during the development of autoimmune diabetes
Immunology and Cell Biology, Vol. 88, Núm. 7, pp. 734-745
-
Peptides targeting toll-like receptor signalling pathways for novel immune therapeutics
Current Pharmaceutical Design, Vol. 16, Núm. 9, pp. 1063-1080
2009
-
Pituitary adenylyl cyclase-activating polypeptide is an intrinsic regulator of Treg abundance and protects against experimental autoimmune encephalomyelitis
Proceedings of the National Academy of Sciences of the United States of America, Vol. 106, Núm. 6, pp. 2012-2017
2008
-
Immunoregulatory properties of vasoactive intestinal peptide in human T cell subsets: Implications for rheumatoid arthritis
Brain, Behavior, and Immunity, Vol. 22, Núm. 3, pp. 312-317
-
VIP balances innate and adaptive immune responses induced by specific stimulation of TLR2 and TLR4
Peptides, Vol. 29, Núm. 6, pp. 948-956